市場調査レポート

商品コード

1235934

がん登録ソフトウェア市場：2028年までの予測- タイプ、データベースタイプ、機能、デプロイメントモデル、エンドユーザー、地域別の世界分析

Cancer Registry Software Market Forecasts to 2028 - Global Analysis By Type, Database Type, Functionality, Deployment Model, End User and Geography

出版日: 2023年03月03日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 175+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 655,285円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 828,975円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 1,002,665円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,184,250円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のがん登録ソフトウェア市場は、2022年に597億2000万米ドルを占め、2028年には1123億2000万米ドルに達すると予測され、予測期間中に11.1%のCAGRで成長するとされています。

がん登録ソフトウェアは、国や州の登録のためのデータ収集を自動化し、さまざまな治療レジメンの有効性を追跡するのに役立ちます。さらに、州登録によって収集されたデータは、病態のより良い理解と治療に役立ちます。収集された情報は、タバコの使用、日光への暴露、化学物質や放射線への暴露などの環境リスクなどの危険因子を特定するのに重要です。また、このデータは、スクリーニングや治療の選択肢を追跡調査し、改善すべき場所を決定するためにも必要です。さらに、レジストリのデータは、研究機関ががんの管理、治療、予防プログラムの効果を測定するのに役立ちます。

Proteus Breachによると、ヘルスケア分野では2019年に4140万件という膨大な数の患者記録が侵害されました。

市場力学です。

促進要因

がん患者の有病率の増加

乳がん、子宮頸がん、前立腺がんは、米国や欧州の人口に非常に多く見られるがんです。動向の把握や原因究明のために、医学研究者は、がんと診断された人口、治療中の患者数、死亡率など、がんに関する最新のデータを必要としています。ヘルスケア関係者は、治療や啓発のために購入する機器や薬剤の量を判断するために、がんの発生率統計を必要としています。データの収集、保存、管理のためにがん登録システムの利用が増加していることは、予測期間中、市場の焦点に好影響を与えるでしょう。

抑制要因

データのプライバシーとセキュリティ

このシステムは非常に個人的なデータを収集するため、データのプライバシーとセキュリティの問題が、予測期間中、がん登録ソフトウェア市場にとって大きな障壁となるであろう。がん登録は、患者の人口統計、腫瘍の特徴、治療、病気の転帰などの情報を収集します。政府機関は、情報の安全な管理を保証するために、新しい規制や法律の施行に注力しています。消費者の健康データの保護とプライバシーのために、医療保険の相互運用性と説明責任に関する法律や米国保健社会福祉省（HHS）にも様々な連邦規制が記載されています。

機会

オンコロジーのための臨床研究の増加

新規のがん治療技術を開発するために、製薬会社や研究機関によって臨床試験が行われています。臨床試験や臨床研究中の登録データの詳細な分析は、がんの原因や治療法を適切に監視するための特定に役立ちます。がん登録は、研究機関や製薬会社によって、第III相および第IV相の臨床研究中のフォローアップ資料として使用されています。洗練されたがん登録ソフトウェアの開発は、公的および私的ながん登録組織のデータ品質向上を支援します。これは、今後数年間の市場の拡大に貢献するでしょう。

脅威

相互運用性・統合性の欠如

EHRシステムと独立したがん患者登録ソフトウェアとの間に接続性がないため、新しい代替手段の開発が妨げられています。このようなデータ交換の問題は、国や地域全体で普遍的な医療情報交換システムが構築されるまで、異なるEHRシステム間で患者記録をインポートまたはエクスポートするための手作業が必要となることが予想されます。その結果、完全な互換性がないEHRが広く採用されることは、がん患者登録ソフトウェアサプライヤーにとって大きな問題となります。

COVID-19の影響

COVID-19のパンデミックのため、パンデミックの間、がんの診断はかなり減少し、化学療法、手術、その他のサポートするがん治療も減少しました。内視鏡的切除術後、外科的切除術後、ポリープ切除術後のがんを延期するよう医師から要請されました。また、感染リスクの高いがん患者の検診を延期するよう勧告され、治療業務の縮小につながっています。疾病管理資産としてのレジストリ運営に将来的に資金を提供することを政府が約束し、電子報告システムへの移行が進めば、がんサーベイランスの世界の持続可能性を確保することができます。

予測期間中、統合ソフトウェア部門が最大となる見込み

統合ソフトウェア分野は、地域腫瘍学ネットワークとソフトウェアを統合する需要の増加により、有利な成長を遂げると推定されます。これは、患部の地理的な位置を追跡し、治療介入を評価するのに役立つと思われます。また、病気の負担や治療プログラムの成功に関するデータの収集にも貢献します。さらに、スクリーニングで検出されたがんを特定し、評価手順を改善するために、スクリーニングアーカイブとの連携が必要です。これらの要因が、今後数年間、このセグメントの拡大を促進すると予測されます。

予測期間中、商用データベース分野のCAGRが最も高くなると予想される

商用データベースは、公開データベースと比較してデータの安全性が高いという利点があるため、予測期間中に最も速いCAGRの成長が見込まれます。商用データベースは、ほとんどの連邦政府の要件や規範に準拠しています。また、データは構造化されており、追跡も簡単です。商用技術により、疾病管理予防センター（CDC）などの政府研究機関や中央がん登録機関間でのデータ伝送が可能になります。

最もシェアの大きい地域

北米は、インフラが整備されていることから、予測期間中に最大の市場シェアを占めると予想されています。この地域の高度なインフラと、イノベーションのための研究開発への投資の増加は、がん登録ソフトウェア市場の成長を促進する重要な要因です。米国国立衛生研究所（NIH）によると、がんは米国で2番目に高い死亡原因となっています。この地域では、タバコの使用や運動不足などに起因するがんの発生率が上昇しており、市場拡大の原動力となっています。

CAGRが最も高い地域。

アジア太平洋地域は、政府の取り組みが活発化していることから、予測期間中に最も高いCAGRを示すと予測されます。日本では、厚生労働省が国内のヘルスケアインフラを強化するためのプロジェクトを立ち上げています。また、中国では第12次5カ年計画で地域ヘルスケア情報ネットワーク（RHIN）の整備が打ち出されました。さらに、中国やインドなどの低コスト製造国への医薬品ビジネスの移動が、アジア太平洋の産業を前進させています。

主な発展を遂げました。

2022年3月、エレクタは、National Health Service Supply Chain（NHSSC）が、放射線治療データを安全で拡張性の高いプラットフォームで集中管理・分析するエレクタのProKnowソフトウェアソリューションを複数ライセンス発注し、全国のNHSイングランド（NHSE）の放射線腫瘍学施設にアクセス可能になったと述べた。

2018年11月、オンコはOncoLog Version 4.4.0をアップグレードし、NAACCR、AJCC、CoC、SEERによって義務付けられた最新の要件を盛り込みました。

当社のレポートが提供するもの

地域および国レベルセグメントの市場シェア評価
新規参入企業への戦略的提言
2020年、2021年、2022年、2025年、2028年の市場データを網羅
市場促進要因（市場動向、制約要因、機会、脅威、課題、投資機会、推奨事項など）
市場推定に基づく主要なビジネスセグメントにおける戦略的な提言
競合情勢とその動向
詳細な戦略、財務、最近の動向を含む企業プロファイル
サプライチェーンの動向は、最新の技術進歩をマッピングしています。

無料カスタマイズの提供

本レポートをご購入いただいたお客様には、以下のいずれかの無料カスタマイズをご提供いたします。

企業プロファイル
- 追加市場プレイヤーの包括的なプロファイリング（最大3名まで）
- キープレイヤーのSWOT分析（3名まで）
地域別セグメント
- お客様のご希望に応じて、主要国の市場推計・予測・CAGRを提供（注：フィージビリティチェック別。）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要プレイヤーのベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東

第11章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

IBM Corporation
McKesson Corporation
Himagine Solutions Inc.
CONDUENT Inc.
C/Net Solutions
Elekta AB
Rocky Mountain Cancer Data Systems
Ordinal Data Inc.
Electronic Registry Systems Inc.
Onco Inc.
F. Hoffmann-La Roche Ltd
Netdox Health Pvt. Ltd.
Centers for Disease Control and Prevention

図表

List of Tables

Table 1 Global Cancer Registry Software Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 3 Global Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 4 Global Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 5 Global Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 6 Global Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 7 Global Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 8 Global Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 9 Global Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 10 Global Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 11 Global Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 12 Global Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 13 Global Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 14 Global Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 15 Global Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 16 Global Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 17 Global Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 18 Global Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 19 Global Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 20 Global Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 21 Global Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
Table 22 North America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
Table 23 North America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 24 North America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 25 North America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 26 North America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 27 North America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 28 North America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 29 North America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 30 North America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 31 North America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 32 North America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 33 North America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 34 North America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 35 North America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 36 North America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 37 North America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 38 North America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 39 North America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 40 North America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 41 North America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 42 North America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
Table 43 Europe Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
Table 44 Europe Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 45 Europe Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 46 Europe Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 47 Europe Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 48 Europe Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 49 Europe Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 50 Europe Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 51 Europe Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 52 Europe Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 53 Europe Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 54 Europe Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 55 Europe Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 56 Europe Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 57 Europe Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 58 Europe Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 59 Europe Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 60 Europe Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 61 Europe Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 62 Europe Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 63 Europe Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
Table 64 Asia Pacific Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
Table 65 Asia Pacific Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 66 Asia Pacific Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 67 Asia Pacific Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 68 Asia Pacific Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 69 Asia Pacific Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 70 Asia Pacific Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 71 Asia Pacific Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 72 Asia Pacific Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 73 Asia Pacific Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 74 Asia Pacific Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 75 Asia Pacific Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 76 Asia Pacific Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 77 Asia Pacific Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 78 Asia Pacific Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 79 Asia Pacific Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 80 Asia Pacific Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 81 Asia Pacific Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 82 Asia Pacific Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 83 Asia Pacific Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 84 Asia Pacific Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
Table 85 South America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
Table 86 South America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 87 South America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 88 South America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 89 South America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 90 South America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 91 South America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 92 South America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 93 South America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 94 South America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 95 South America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 96 South America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 97 South America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 98 South America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 99 South America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 100 South America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 101 South America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 102 South America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 103 South America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 104 South America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 105 South America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
Table 106 Middle East & Africa Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
Table 107 Middle East & Africa Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
Table 108 Middle East & Africa Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
Table 109 Middle East & Africa Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
Table 110 Middle East & Africa Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
Table 111 Middle East & Africa Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
Table 112 Middle East & Africa Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
Table 113 Middle East & Africa Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
Table 114 Middle East & Africa Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
Table 115 Middle East & Africa Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
Table 116 Middle East & Africa Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
Table 117 Middle East & Africa Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
Table 118 Middle East & Africa Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
Table 119 Middle East & Africa Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
Table 120 Middle East & Africa Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
Table 121 Middle East & Africa Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
Table 122 Middle East & Africa Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
Table 123 Middle East & Africa Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
Table 124 Middle East & Africa Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
Table 125 Middle East & Africa Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
Table 126 Middle East & Africa Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)

Product Code: SMRC22531

According to Stratistics MRC, the Global Cancer Registry Software Market is accounted for $59.72 billion in 2022 and is expected to reach $112.32 billion by 2028 growing at a CAGR of 11.1% during the forecast period. The cancer registry software automates data collecting for national and state registries, which aids in tracking the effectiveness of various treatment regimens. Furthermore, the data collected by the state registries aid in better understanding and treatment of the condition. The information gathered is critical in identifying risk factors such as tobacco usage, sun exposure, or environmental risks such as chemical and radiation exposure. This data is also required for determining where screening and treatment options should be tracked and improved. Furthermore, registry data can help research institutes measure the effectiveness of cancer management, treatment, and preventive programmes.

According to Proteus Breach, healthcare sector saw a massive 41.4 million patient records breached in 2019.

Market Dynamics:

Driver:

Growing prevalence of cancer cases

Breast, cervical, and prostate cancers are extremely common in the populations of the United States and Europe. To track trends and examine the possible causes of cancer, medical researchers require up-to-date data on cancer, such as the population diagnosed with cancer, patients undergoing treatment, and mortality rate. Healthcare professionals require cancer incidence statistics in order to make judgements about the amount of equipment and drugs to purchase for treatment and awareness. The increased usage of cancer registry systems for data collecting, storage, and management would have a favourable impact on the market focus during the projection period.

Restraint:

Data privacy and security

Data privacy and security issues, as the system collects highly personal data, will be a major barrier for the cancer registry software market over the projection period. Cancer registries collect information such as patient demographics, tumour features, treatment, and disease outcome. Government agencies are concentrating on the implementation of new regulations and laws to ensure the safe management of information. Various federal regulations are also listed in the Health Insurance Portability and Accountability Act and the US Department of Health and Human Services (HHS) for the protection and privacy of consumer health data.

Opportunity:

Increasing clinical research for oncology

Clinical trials are being conducted by pharmaceutical companies and research organisations in order to develop novel cancer treatment techniques. Clinical trials and in-depth analyses of registry data during clinical research aid in the identification of proper monitoring of cancer causes and therapies. Cancer registries are used by research institutes and pharmaceutical corporations as a follow-up source during phase III and phase IV clinical studies. The development of sophisticated cancer registry software assists public and private cancer registry organisations in improving data quality. This will help the market's expansion in the coming years.

Threat:

Lack of interoperability and integration

The lack of connectivity between EHR systems and independent cancer patient registration software has impeded the development of novel alternatives. These types of data exchange problems are expected to continue to necessitate manual methods for importing or exporting patient records between different EHR systems until a universal health information exchange system is built throughout a country/region. As a result, broad adoption of EHRs that are not fully compatible poses a significant problem for cancer patient registry software suppliers.

COVID-19 Impact

Because of the COVID-19 pandemic, cancer diagnoses declined considerably during the pandemic, as did chemotherapy, surgery, and other supporting cancer treatments. Doctors were urged to postpone post-endoscopic resection, surgical resection of cancer, and post-polypectomy cancer. They also recommended that screening for high-risk cancer patients be postponed due to the risk of infection, which resulted in a reduction in treatment operations. A government commitment to fund future registry operations as a disease control asset, along with a shift towards electronic reporting systems, would help to secure the global sustainability of cancer surveillance.

The integrated software segment is expected to be the largest during the forecast period

The integrated software segment is estimated to have a lucrative growth, due to the increasing demand for integrating software with a regional oncology network. This will aid in tracking affected geographic locations and evaluating the treatment intervention. It will also contribute in the collection of data on illness burden and the success of treatment programmes. Furthermore, linkage with screening archives is required to identify screen-detected cancers and improve evaluation procedures. These factors are projected to drive the expansion of this segment in the next years.

The commercial database segment is expected to have the highest CAGR during the forecast period

The commercial database segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its advantage of data safety as compared to the public database. The commercial database complies with most federal requirements and codes. The data is also well-structured and simple to follow. Commercial technologies enable data transmission among government research agencies such as the Centers for Disease Control and Prevention (CDC) and central cancer registries.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of developed infrastructure. The region's advanced infrastructure and increased investment in research & development for innovation are important factors driving the growth of the cancer registry software market. Cancer is the second highest cause of mortality in the United States, according to the National Institutes of Health (NIH). The rising incidence of cancer in this region, owing to cigarette use and a lack of physical exercise, among other factors, is fuelling market expansion.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to increasing government initiatives being undertaken in this region. In Japan, the Ministry of Health, Labour, and Welfare has launched projects to strengthen the country's healthcare infrastructure. China has also unveiled its 12th Five-Year Plan to improve the country's Regional Healthcare Information Networks (RHINs). Furthermore, the movement of pharmaceutical businesses to low-cost manufacturing countries such as China and India is moving the Asia Pacific industry forward.

Key players in the market

Some of the key players profiled in the Cancer Registry Software Market include: IBM Corporation, McKesson Corporation, Himagine Solutions Inc., CONDUENT Inc., C/Net Solutions, Elekta AB, Rocky Mountain Cancer Data Systems, Ordinal Data Inc., Electronic Registry Systems Inc., Onco Inc., F. Hoffmann-La Roche Ltd, Netdox Health Pvt. Ltd. and Centers for Disease Control and Prevention

Key Developments:

In March 2022, Elekta stated that National Health Service Supply Chain (NHSSC) had ordered multiple licenses for Elekta's ProKnow software solution, which centralizes and analyzes radiotherapy data in a secure, scalable platform, accessible to the NHS England's (NHSE's) radiation oncology facilities throughout the country.

In November 2018, Onco upgraded the OncoLog Version 4.4.0 to include the newest requirements mandated by NAACCR, AJCC, CoC and SEER.

Types Covered:

Standalone Software
Integrated Software

Database Types Covered:

Public Database
Commercial Database

Functionalities Covered:

Product Outcome Evaluation
Cancer Reporting to Meet State and Federal Regulations
Medical Research & Clinical Studies
Patient Care Management

Deployment Models Covered:

Cloud-based
On-premise

End Users Covered:

Research Centre
Hospitals & Medical Practices
Private Payers
Pharmaceutical, Biotechnology, and Medical Device Companies
Government Organizations & Third-Party Administrators

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Registry Software Market, By Type

5.1 Introduction
5.2 Standalone Software
5.3 Integrated Software

6 Global Cancer Registry Software Market, By Database Type

6.1 Introduction
6.2 Public Database
6.3 Commercial Database

7 Global Cancer Registry Software Market, By Functionality

7.1 Introduction
7.2 Product Outcome Evaluation
7.3 Cancer Reporting to Meet State and Federal Regulations
7.4 Medical Research & Clinical Studies
7.5 Patient Care Management

8 Global Cancer Registry Software Market, By Deployment Model

8.1 Introduction
8.2 Cloud-based
8.3 On-premise

9 Global Cancer Registry Software Market, By End User

9.1 Introduction
9.2 Research Centre
9.3 Hospitals & Medical Practices
9.4 Private Payers
9.5 Pharmaceutical, Biotechnology, and Medical Device Companies
9.6 Government Organizations & Third-Party Administrators

10 Global Cancer Registry Software Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 IBM Corporation
12.2 McKesson Corporation
12.3 Himagine Solutions Inc.
12.4 CONDUENT Inc.
12.5 C/Net Solutions
12.6 Elekta AB
12.7 Rocky Mountain Cancer Data Systems
12.8 Ordinal Data Inc.
12.9 Electronic Registry Systems Inc.
12.10 Onco Inc.
12.11 F. Hoffmann-La Roche Ltd
12.12 Netdox Health Pvt. Ltd.
12.13 Centers for Disease Control and Prevention